Journal
CLINICS IN DERMATOLOGY
Volume 30, Issue 6, Pages 657-661Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.clindermatol.2011.09.018
Keywords
-
Categories
Ask authors/readers for more resources
After a long period of relative inactivity in the introduction of new antifungals, more recently a few new drugs of already existing classes have been introduced. These represent small or large advantages and differences compared with existing available alternative therapy for deep and systemic mycoses. The 3 newest drugs include posaconazole, micafungin, and anidulafungin, whose pharmacology, toxicology, and indications are presented. (C) 2012 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available